Management of interleukin-2-induced severe bronchoconstriction

Eur Respir J. 2007 Mar;29(3):612-3. doi: 10.1183/09031936.00152706.
No abstract available

Publication types

  • Letter

MeSH terms

  • Administration, Inhalation
  • Adrenergic beta-Agonists / administration & dosage*
  • Aged
  • Aged, 80 and over
  • Albuterol / administration & dosage
  • Albuterol / analogs & derivatives*
  • Androstadienes / administration & dosage*
  • Anti-Inflammatory Agents / administration & dosage*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Bronchial Diseases / chemically induced*
  • Bronchial Diseases / drug therapy*
  • Bronchodilator Agents / administration & dosage*
  • Constriction, Pathologic / chemically induced
  • Constriction, Pathologic / drug therapy
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Female
  • Fluticasone
  • Forced Expiratory Volume / drug effects
  • Hemangioendothelioma / drug therapy*
  • Humans
  • Infusions, Intravenous
  • Injections, Intralesional
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / adverse effects*
  • Male
  • Middle Aged
  • Premedication
  • Salmeterol Xinafoate
  • Skin Neoplasms / drug therapy*

Substances

  • Adrenergic beta-Agonists
  • Androstadienes
  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Bronchodilator Agents
  • Delayed-Action Preparations
  • Interleukin-2
  • Salmeterol Xinafoate
  • Fluticasone
  • Albuterol